Schedule a consultation to discuss Semaglutide, Tirzepatide, oral options, labs, and ongoing support
Kandhari R, Kaur I, Sharma D
Clinical trials have shown that weight loss with GLP-1 agonists typically occurs over several months, with the most significant results observed after a year of consistent treatment
With increasing frequency over the past few years, optometrists across the country have gotten referrals from internists requesting baseline diabetic retinopathy (DR) screenings for patients about to start therapy with one of the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists such as semaglutide (Ozempic, Novo Nordisk), tirzepatide (Mounjaro, Eli Lilly) and dulaglutide (Trulicity, Eli Lilly
Early research described Ipamorelin as a selective growth hormone secretagogue and noted that it did not significantly raise ACTH or cortisol compared with GHRH stimulation
An incorrectly sequenced CJC-1295 might not bind to the pituitary receptors correctly, rendering it useless
